Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos, a Belgium-based biotechnology company, has expanded the osteoarthritis alliance with GlaxoSmithKline to include two additional drug targets.
Subscribe to our email newsletter
For this expansion, Galapagos receives a payment of E2 million cash from GlaxoSmithKline (GSK). This payment is in addition to the existing alliance terms, making the total alliance now worth up to E188 million.
Including the latest payment, Galapagos has received a total of E17.9 million in payments from GSK under this alliance.